Table 4.

Median progression-free survival times and survival rates relative to molecular subtypes and IPAQ categories

Molecular subtype	IPAQ	Patients	Events	Median survival time (months) (95% CI)	6-month survival rate (95% CI)	12-month survival rate (95% CI)	24-month survival rate (95% CI)	36-month survival rate (95% CI)
HRpos: Luminal A-like	low	75	61	10.1 (8.7, 13.5)	0.67 (0.57, 0.79)	0.39 (0.29, 0.51)	0.22 (0.14, 0.34)	0.16 (0.09, 0.28)
	moderate	425	354	8.3 (7.2, 9.9)	0.60 (0.55, 0.65)	0.39 (0.35, 0.44)	0.25 (0.21, 0.29)	0.16 (0.13, 0.21)
	high	49	44	9.6 (6.8, 13.7)	0.65 (0.52, 0.80)	0.40 (0.28, 0.56)	0.17 (0.09, 0.32)	0.07 (0.02, 0.21)
HRpos: Luminal B-like	low	18	17	9.9 (5.7, 17.9)	0.67 (0.48, 0.92)	0.33 (0.17, 0.64)	0.11 (0.03, 0.41)	0.06 (0.01, 0.37)
	moderate	194	179	6.5 (5.3, 7.9)	0.52 (0.45, 0.60)	0.26 (0.21, 0.33)	0.18 (0.13, 0.25)	0.08 (0.05, 0.13)
	high	32	29	6.4 (3.7, 11.3)	0.52 (0.37, 0.74)	0.29 (0.17, 0.50)	0.17 (0.08, 0.36)	0.12 (0.05, 0.29)
HER2pos	low	26	19	17.9 (4.0, 33.7)	0.64 (0.48, 0.86)	0.56 (0.39, 0.79)	0.28 (0.15, 0.55)	0.24 (0.11, 0.50)
	moderate	217	166	9.0 (7.1, 12.2)	0.63 (0.57, 0.70)	0.43 (0.37, 0.50)	0.23 (0.18, 0.30)	0.19 (0.14, 0.25)
	high	35	32	5.1 (3.0, 10.5)	0.49 (0.35, 0.69)	0.25 (0.14, 0.44)	0.19 (0.10, 0.37)	0.16 (0.07, 0.34)
TNBC	low	11	11	1.8 (1.3, NA)	0.27 (0.10, 0.71)	NA	NA	NA
	moderate	104	93	4.3 (3.2, 5.9)	0.39 (0.30, 0.49)	NA	NA	NA
	high	20	19	4.0 (3.4, 7.4)	0.39 (0.23, 0.68)	NA	NA	NA

HER2pos Human epidermal growth factor receptor 2 positive, HRpos Hormone receptor-positive, TNBC Triple negative breast cancer, IPAQ International Physical Activity Questionnaire, CI Confidence interval, NA Not applicable – could not be calculated